Vivos Therapeutics (NASDAQ:VVOS) Receives “Buy” Rating from Ascendiant Capital Markets

Ascendiant Capital Markets restated their buy rating on shares of Vivos Therapeutics (NASDAQ:VVOS) in a research report report published on Wednesday,Benzinga reports. The brokerage currently has a $6.60 target price on the stock.

Separately, Alliance Global Partners lowered their target price on shares of Vivos Therapeutics from $8.25 to $6.00 and set a “buy” rating for the company in a report on Tuesday.

Vivos Therapeutics Trading Up 2.1 %

NASDAQ VVOS opened at $2.89 on Wednesday. Vivos Therapeutics has a 52 week low of $1.91 and a 52 week high of $48.79. The firm has a 50 day moving average of $2.78 and a two-hundred day moving average of $2.52.

About Vivos Therapeutics

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.